Cannabis and Cannabinoids in the Perioperative Period.
Journal
Anesthesia and analgesia
ISSN: 1526-7598
Titre abrégé: Anesth Analg
Pays: United States
ID NLM: 1310650
Informations de publication
Date de publication:
13 May 2022
13 May 2022
Historique:
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
aheadofprint
Résumé
Cannabis use is increasingly common, and with a growing number of jurisdictions implementing legalization frameworks, it is likely that providers will encounter more patients who use cannabis. Therefore, it is important for providers to understand the implications of cannabis use and practical considerations for the perioperative period. Cannabis affects multiple organ systems and may influence intraoperative anesthesia, as well as postoperative pain management. The effects of cannabis and key anesthetic considerations are reviewed here.
Identifiants
pubmed: 35551150
doi: 10.1213/ANE.0000000000006070
pii: 00000539-990000000-00369
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2022 International Anesthesia Research Society.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4:1614–1648.
Alexander JC, Joshi GP. A review of the anesthetic implications of marijuana use. Proc (Bayl Univ Med Cent). 2019;32:365–371.
Echeverria-Villalobos M, Todeschini AB, Stoicea N, Fiorda-Diaz J, Weaver T, Bergese SD. Perioperative care of cannabis users: a comprehensive review of pharmacological and anesthetic considerations. J Clin Anesth. 2019;57:41–49.
Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 2005;168:1–51.
Di Marzo V, Fontana A, Cadas H,, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372:686–691.
Howlett AC, Barth F, Bonner TI,, et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161–202.
Howlett AC, Berglund B, Melvin LS. Cannabinoid receptor agonists and antagonists. Curr Pharm Des. 1995;1:343–354.
Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012;76:70–81.
Tapley P, Kellett S. Cannabis-based medicines and the perioperative physician. Periop Med. 2019;8.
Chung EY, Cha HJ, Min HK, Yun J. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. Arch Pharm Res. 2021;44:402–413.
Elsohly MA, Gul W. Constituents of cannabis sativa. Handbook of Cannabis. Oxford University Press; 2014.
Elsohly MA. Chemical constituents of cannabis. In: Press HIH, ed. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. The Haworth Integrative Healing Press; 2002.
Gaoni Y,, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646–1647.
Small E. Evolution and classification of cannabis sative (marijuana, hemp) in relation to human utilization. Bot Rev. 2015;81:189–264.
Bautista JL, Yu S, Tian L. Flavonoids in Cannabis sativa: biosynthesis, bioactivities, and biotechnology. ACS Omega. 2021;6:5119–5123.
Narouze S. Antinociception mechanisms of action of cannabinoid-based medicine: an overview for anesthesiologists and pain physicians. Reg Anesth Pain Med. 2021;46:240–250.
Amin RH, Ali DW. Pharmacology of medical cannabis. Adv Exp Med Biol. 2019;1162:151–165.
Vergara D, Bidwell LC, Gaudino R,, et al. Compromised external validity: federally produced cannabis does not reflect legal markets. Sci Rep. 2017;7:46528.
ElSohly MA, Chandra S, Radwan M, Majumdar CG, Church JC. A comprehensive review of cannabis potency in the United States in the last decade. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6:603–606.
Cuttler C, LaFrance EM, Stueber A. Acute effects of high-potency cannabis flower and cannabis concentrates on everyday life memory and decision making. Sci Rep. 2021;11:13784.
Leas EC, Hendrickson EM, Nobles AL,, et al. Self-reported cannabidiol (CBD) use for conditions with proven therapies. JAMA Netw Open. 2020;3:e2020977.
Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318:1708–1709.
Williams AR, Olfson M, Kim JH, Martins SS, Kleber HD. Older, less regulated medical marijuana programs have much greater enrollment rates than newer “medicalized” programs. Heal Aff. 2016;35:480–488.
Zhang BH, Saud H, Sengupta N,, et al. Effect of preoperative cannabis use on perioperative outcomes: a retrospective cohort study. Reg Anesth Pain Med. 2021;46:650–655.
Chiu RG, Patel S, Siddiqui N, Nunna RS, Mehta AI. Cannabis abuse and perioperative complications following inpatient spine surgery in the United States. Spine (Phila Pa 1976). 2021;46:734–743.
Lipari RN, Parkl-Lee E. 2018 NSDUH Annual National Report CBHSQ Data. https://www.samhsa.gov/data/report/2018-nsduh-annual-nationalreport.
Goel A, McGuinness B, Jivraj NK,, et al. Cannabis use disorder and perioperative outcomes in major elective surgeries: a retrospective cohort analysis. Anesthesiology. 2020;132:625–635.
McGuinness B, Goel A, Elias F, Rapanos T, Mittleman MA, Ladha KS. Cannabis use disorder and perioperative outcomes in vascular surgery. J Vasc Surg. 2021;73:1376–1387.e3.
Haroutounian S, Gilron I, Belton J, et al. Societal issues and policy implications related to the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 2021;162(suppl 1):S110–S116.
Goodman S, Wadsworth E, Leos-Toro C, Hammond D; International Cannabis Policy Study team. Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets. Int J Drug Policy. 2020;76:102658.
Ladha KS, Manoo V, Virji AF,, et al. The impact of perioperative cannabis use: a narrative scoping review. Cannabis Cannabinoid Res. 2019;4:219–230.
Bahji A, Stephenson C. International perspectives on the implications of cannabis legalization: a systematic review and thematic analysis. Int J Env Res Public Heal. 2019;16:3095.
Touil N, Lavand’homme P. Cannabis hyperalgesia: a phenomenon underestimated in the peri-operative period? Eur J Anaesthesiol. 2019;36:623–624.
Liu CW, Bhatia A, Buzon-Tan A,, et al. Weeding out the problem: the impact of preoperative cannabinoid use on pain in the perioperative period. Anesth Analg. 2019;129:874–881.
Meacher M, Nutt D, Liebling J, Murray RM, Gridley A. Should the supply of cannabis be legalised now? BMJ. 2019;366:l4473.
Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021;7:16.
Khelemsky Y, Goldberg AT, Hurd YL,, et al. Perioperative patient beliefs regarding potential effectiveness of marijuana (cannabinoids) for treatment of pain: a prospective population survey. Reg Anesth Pain Med. 2017;42:652–659.
Lovecchio F, Langhans MT, Bennett T,, et al. Prevalence of cannabidiol use in patients with spine complaints: results of an anonymous survey. Int J Spine Surg. 2021;15:663–668.
Runner RP, Luu AN, Nassif NA,, et al. Use of tetrahydrocannabinol and cannabidiol products in the perioperative period around primary unilateral total hip and knee arthroplasty. J Arthroplasty. 2020;35:S138–S143.
Benowitz NL, Rosenberg J, Rogers W, Bachman J, Jones RT. Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther. 1979;25:440–446.
Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart. 2000;83:627–633.
Johnson S, Domino EF. Some cardiovascular effects of marihuana smoking in normal volunteers. Clin Pharmacol Ther. 1971;12:762–768.
Gregg JM, Campbell RL, Levin KJ, Ghia J, Elliott RA. Cardiovascular effects of cannabinol during oral surgery. Anesth Analg. 1976;55:203–213.
Tashkin DP. Marijuana and lung disease. Chest. 2018;154:653–663.
Kunos G, Járai Z, Bátkai S, . Endocannabinoids as cardiovascular modulators. Chem Phys Lipids. 2000;108:159–168.
Singh A, Saluja S, Kumar A, . Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther. 2018;7:45–59.
Baranchuk A, Johri AM, Simpson CS, Methot M, Redfearn DP. Ventricular fibrillation triggered by marijuana use in a patient with ischemic cardiomyopathy: a case report. Cases J. 2008;1:373.
Aronow WS, Cassidy J. Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med. 1974;291:65–67.
Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103:2805–2809.
Benyó Z, Ruisanchez É, Leszl-Ishiguro M, Sándor P, Pacher P. Endocannabinoids in cerebrovascular regulation. Am J Physiol Heart Circ Physiol. 2016;310:H785–H801.
Szekeres M, Nádasy GL, Turu G,, et al. Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors. J Biol Chem. 2012;287:31540–31550.
Wagner JA, Járai Z, Bátkai S, Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol. 2001;423:203–210.
Rumalla K, Reddy AY, Mittal MK. Recreational marijuana use and acute ischemic stroke: a population-based analysis of hospitalized patients in the United States. J Neurol Sci. 2016;364:191–196.
Tashkin DP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. 2013;10:239–247.
Tashkin DP, Shapiro BJ, Frank IM. Acute pulmonary physiologic effects of smoked marijuana and oral (Delta)9 -tetrahydrocannabinol in healthy young men. N Engl J Med. 1973;289:336–341.
Vachon L, FitzGerald MX, Solliday NH, Gould IA, Gaensler EA. Single-dose effects of marihuana smoke. Bronchial dynamics and respiratory-center sensitivity in normal subjects. N Engl J Med. 1973;288:985–989.
Calignano A, Desarnaud K, Giuffrida A, et al. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature. 2000;408:96–101.
Mallat A, Roberson J, Brock-Utne JG. Preoperative marijuana inhalation–an airway concern. Can J Anaesth. 1996;43:691–693.
Bloom JW, Kaltenborn WT, Paoletti P, Camilli A, Lebowitz MD. Respiratory effects of non-tobacco cigarettes. Br Med J (Clin Res Ed). 1987;295:1516–1518.
Tan WC, Lo C, Jong A, ; Vancouver Burden of Obstructive Lung Disease (BOLD) Research Group. Marijuana and chronic obstructive lung disease: a population-based study. CMAJ. 2009;180:814–820.
Macleod J, Robertson R, Copeland L, McKenzie J, Elton R, Reid P. Cannabis, tobacco smoking, and lung function: a cross-sectional observational study in a general practice population. Br J Gen Pract. 2015;65:e89–e95.
Tashkin DP, Calvarese BM, Simmons MS, Shapiro BJ. Respiratory status of seventy-four habitual marijuana smokers. Chest. 1980;78:699–706.
Hancox RJ, Poulton R, Ely M,, et al. Effects of cannabis on lung function: a population-based cohort study. Eur Respir J. 2010;35:42–47.
Taylor DR, Poulton R, Moffitt TE, Ramankutty P, Sears MR. The respiratory effects of cannabis dependence in young adults. Addiction. 2000;95:1669–1677.
MacCarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agrò A. Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem. 2001;268:819–825.
Maccarrone M, Bari M, Menichelli A, Del Principe D, Agrò AF. Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett. 1999;447:277–282.
Coetzee C, Levendal RA, van de Venter M, Frost CL. Anticoagulant effects of a cannabis extract in an obese rat model. Phytomedicine. 2007;14:333–337.
Zakreska A, Gredzinksi T, Kisiel W, Chabielska E. Cannabinoids and haemostasis. Postep Hig Med Dosw. 2016;70:760–774.
Formukong EA, Evans AT, Evans FJ. The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. On human and rabbit platelet aggregation. J Pharm Pharmacol. 1989;41:705–709.
Schaefer CF, Brackett DJ, Gunn CG, Dubowski KM. Decreased platelet aggregation following marihuana smoking in man. J Okla State Med Assoc. 1979;72:435–436.
Moritz E, Austin C, Wahl M,, et al. Notes from the field: outbreak of severe illness linked to the vitamin k antagonist brodifacoum and use of synthetic cannabinoids - Illinois, March–April 2018. MMWR Morb Mortal Wkly Rep. 2018;67:607–608.
Kelkar AH, Smith NA, Martial A, Moole H, Tarantino MD, Roberts JC. An outbreak of synthetic cannabinoid-associated coagulopathy in Illinois. N Engl J Med. 2018;379:1216–1223.
Deusch E, Kress HG, Kraft B, Kozek-Langenecker SA. The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. Anesth Analg. 2004;99:1127–1130.
Trautmann SM, Sharkey KA. The endocannabinoid system and its role in regulating the intrinsic neural circuitry of the gastrointestinal tract. Int Rev Neurobiol. 2015;125:85–126.
Sharkey KA, Wiley JW. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology. 2016;151:252–266.
Sharkey KA, Darmani NA, Parker LA. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol. 2014;722:134–146.
Van Sickle MD, Duncan M, Kingsley PJ, . Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329–332.
Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53:1566–1570.
Wallace EA, Andrews SE, Garmany CL, Jelley MJ. Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm. South Med J. 2011;104:659–664.
Abalo R, Vera G, López-Pérez AE, Martínez-Villaluenga M, Martín-Fontelles MI. The gastrointestinal pharmacology of cannabinoids: focus on motility. Pharmacology. 2012;90:1–10.
Camilleri M. Cannabinoids and gastrointestinal motility: pharmacology, clinical effects and potential therapeutics in humans. Neurogastroenterol Motil. 2018;30:e13370.
Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut. 2001;48:859–867.
Massa F, Marsicano G, Hermann H, . The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004;113:1202–1209.
Burggren AC, Shirazi A, Ginder N, London ED. Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives. Am J Drug Alcohol Abuse. 2019;45:563–579.
Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77:299–318.
Metrik J, Kahler CW, Reynolds B, . Balanced placebo design with marijuana: pharmacological and expectancy effects on impulsivity and risk taking. Psychopharmacology (Berl). 2012;223:489–499.
Morrison PD, Zois V, McKeown DA, . The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009;39:1607–1616.
Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology. 2006;31:2296–2303.
Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001;56:1059–1068.
Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84:2477–2482.
Gregg JM, Small EW, Moore R, Raft D, Toomey TC. Emotional response to intravenous delta9tetrahydrocannabinol during oral surgery. J Oral Surg. 1976;34:301–313.
Hill KP, Palastro MD, Johnson B, Ditre JW. Cannabis and pain: a clinical review. Cannabis Cannabinoid Res. 2017;2:96–104.
Vučković S, Srebro D, Vujović KS, Vučetić Č, Prostran M. Cannabinoids and pain: new insights from old molecules. Front Pharmacol. 2018;9:1259.
Haleem R, Wright R. A scoping review on clinical trials of pain reduction with cannabis administration in adults. J Clin Med Res. 2020;12:344–351.
Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20:E755–E796.
Abdallah FW, Hussain N, Weaver T, Brull R. Analgesic efficacy of cannabinoids for acute pain management after surgery: a systematic review and meta-analysis. Reg Anesth Pain Med. 2020;45:509–519.
Volkow ND, Swanson JM, Evins AE,, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73:292–297.
Fontes MA, Bolla KI, Cunha PJ,, et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry. 2011;198:442–447.
Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. Psychol Addict Behav. 2012;26:496–506.
Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med. 2003;33:15–21.
Cuttler C, McLaughlin RJ, Graf P. Mechanisms underlying the link between cannabis use and prospective memory. PLoS One. 2012;7:e36820.
Crane NA, Schuster RM, Gonzalez R. Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users. J Int Neuropsychol Soc. 2013;19:1009–1015.
Solowij N, Stephens R, Roffman RA, Babor T. Does marijuana use cause long-term cognitive deficits? JAMA. 2002;287:2653–2654.
Bellocchio L, Cervino C, Pasquali R, Pagotto U. The endocannabinoid system and energy metabolism. J Neuroendocrinol. 2008;20:850–857.
Borowska M, Czarnywojtek A, Sawicka-Gutaj N,, et al. The effects of cannabinoids on the endocrine system. Endokrynol Pol. 2018;69:705–719.
Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006;27:73–100.
Hsiao P, Clavijo RI. Adverse effects of cannabis on male reproduction. Eur Urol Focus. 2018;4:324–328.
Brents LK. Marijuana, the endocannabinoid system and the female reproductive system. Yale J Biol Med. 2016;89:175–191.
Williams CM, Kirkham TC. Observational analysis of feeding induced by D9-THC and anandamide. Physiol Behav. 2002;76:241–250.
Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002;136:550–557.
Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol. 2006;69:471–478.
Pagano C, Pilon C, Calcagno A,, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab. 2007;92:4810–4819.
Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol. 2007;267:63–69.
Juan-Picó P, Fuentes E, Bermúdez-Silva FJ,, et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium. 2006;39:155–162.
Bermúdez-Siva FJ, Serrano A, Diaz-Molina FJ,, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol. 2006;531:282–284.
Sankar-Maharaj S, Chen D, Hariharan S. Postoperative shivering among cannabis users at a public hospital in Trinidad, West Indies. J Perianesth Nurs. 2018;33:37–44.
Pryce G, Baker D. Antidote to cannabinoid intoxication: the CB1 receptor inverse agonist, AM251, reverses hypothermic effects of the CB1 receptor agonist, CB-13, in mice. Br J Pharmacol. 2017;174:3790–3794.
Clarke H, Roychoudhury P, Ladha KS,, et al. Daring discourse - yes: practical considerations for cannabis use in the perioperative setting. Reg Anesth Pain Med. 2020;45:524–527.
Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States. J Neurol Sci. 2020;411:116717.
Gofeld M, Robinson S, Faclier G. Administration of nabilone for postoperative pain control in the marijuana-addicted: case study. Acute Pain. 2006;8:29–32.
Ladha KS, McLaren-Blades A, Goel A, et al. Perioperative pain and addiction interdisciplinary network (PAIN): consensus recommendations for perioperative management of cannabis and cannabinoid-based medicine users by a modified Delphi process. Br J Anaesth. 2021;126:304–318.
Flisberg P, Paech MJ, Shah T, Ledowski T, Kurowski I, Parsons R. Induction dose of propofol in patients using cannabis. Eur J Anaesthesiol. 2009;26:192–195.
Ursic M, Babic A, Vake T, Snoj T. The impact of cannabidiol on the induction of isoflurane anesthesia and recovery in Wistar rats. Cannabis Cannabinoid Res. 2021. Published online ahead of print on May 11, 2021. doi: 10.1089/can.2021.0014
P RG. Tolerance to and dependence on psychotropic cannabinoids. The Biological Basis of Drug Tolerance and Dependence. Academic Press, 1991:232–263.
Brand PA, Paris A, Bein B, et al. Propofol sedation is reduced by delta9-tetrahydrocannabinol in mice. Anesth Analg. 2008;107:102–106.
Lynn RSR, Galinkin JL. Cannabis, e-cigarettes and anesthesia. Curr Opin Anaesthesiol. 2020;33:318–326.
Twardowski MA, Link MM, Twardowski NM. Effects of cannabis use on sedation requirements for endoscopic procedures. J Am Osteopat Assoc. 2019;119:307–311.
Thakkar H, Mahindajit A, Taylor D, Roberts L, C J. Conscious sedation for transoesophageal echocardiography in cannabis users. Hear Lung Circ. 2017;26(suppl):S254.
Ibera C, Shalom B, Saifi F, Shruder J, Davidson E. Effects of cannabis extract premedication on anesthetic depth. Harefuah. 2018;157:162–166.
Richtig G, Bosse G, Arlt F, von H C. Cannabis consumption before surgery may be associated with increased tolerance of anesthetic drugs: a case report. Int J Case Rep Images. 2015;6:436–439.
Symons IE. Cannabis smoking and anaesthesia. Anaesthesia. 2002;57:1142–1143.
Holmen IC, Beach JP, Kaizer AM, Gumidyala R. The association between preoperative cannabis use and intraoperative inhaled anesthetic consumption: a retrospective study. J Clin Anesth. 2020;67:109980.
Pacheco F, Roberto T, Romero L, Dimitri I, Duarte IDG. Ketamine induces central nociception mediated by endogenous cannabinoids and activation of CB1 receptors. Neurosci Lett. 2019;699:140–144.
Hallak JE, Dursun SM, Bosi DC,, et al. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:198–202.
Lile JA, Wesley MJ, Kelly TH, Hays LR. Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol. Behav Pharmacol. 2016;27:215–224.
Turcotte D, Doupe M, Torabi M,, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med. 2015;16:149–159.
Tham SM, Angus JA, Tudor EM, Wright CE. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br J Pharmacol. 2005;144:875–884.
Morsch M, Protti DA, Cheng D,, et al. Cannabinoid-induced increase of quantal size and enhanced neuromuscular transmission. Sci Rep. 2018;8:4685.
Alsherbiny MA, Li CG. Medicinal cannabis - potential drug interactions. Med. 2018;6:3.
Uhing MR, Beno DW, Jiyamapa-Serna VA,, et al. The effect of anesthesia and surgery on CYP3A activity in rats. Drug Metab Dispos. 2004;32:1325–1330.
Stott C, White L, Wright S, Wilbraham D, Guy G. A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus. 2013;2:236.
Jamal N, Korman J, Musing M,, et al. Effects of pre-operative recreational smoked cannabis use on opioid consumption following inflammatory bowel disease surgery: a historical cohort study. Eur J Anaesthesiol. 2019;36:705–706.
Bhashyam AR, Heng M, Harris MB, Vrahas MS, Weaver MJ. Self-reported marijuana use is associated with increased use of prescription opioids following traumatic musculoskeletal injury. J Bone Joint Surg Am. 2018;100:2095–2102.
Stevens AJ, Higgins MD. A systematic review of the analgesic efficacy of cannabinoid medications in the management of acute pain. Acta Anaesthesiol Scand. 2017;61:268–280.
Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003;106:169–172.
Hickernell TR, Lakra A, Berg A, Cooper HJ, Geller JA, Shah RP. Should cannabinoids be added to multimodal pain regimens after total hip and knee arthroplasty. J Arthroplast. 2018;33:3637–3641.
Lee BH, Kumar KK, Wu EC, Wu CL. Role of regional anesthesia and analgesia in the opioid epidemic. Reg Anesth Pain Med. 2019;13:rapm-2018-100102.
Weinstein AM, Gorelick DA. Pharmacological treatment of cannabis dependence. Curr Pharm Des. 2011;17:1351–1358.
McAfee J, Boehnke KF, Moser SM, Brummett CM, Waljee JF, Bonar EE. Perioperative cannabis use: a longitudinal study of associated clinical characteristics and surgical outcomes. Reg Anesth Pain Med. 2021;46:137–144.
Shore BJ, Flaugh R, Shannon BA, Curran P, Hogue G. Preoperative considerations for teenagers undergoing orthopaedic surgery: VTE prevention, mental health assessment, vaping, and drug addiction. J Pediatr Orthop. 2021;41:S64–S69.
Moon AS, Smith W, Mullen S,, et al. Marijuana use and mortality following orthopedic surgical procedures. Subst Abus. 2019;40:378–382.
Law TY, Kurowicki J, Rosas S,, et al. Cannabis use increases risk for revision after total knee arthroplasty. J Long Term Eff Med Implants. 2018;28:125–130.
Vakharia RM, Mannino A, Salem HS, Roche MW, Wong CHJ, Mont MA. The association between cannabis use disorder and the outcome following primary total hip arthroplasty: analysis of a nationwide administrative claims database. Bone Jt J. 2021;103-B(7 supple B):111–115.
Vakharia RM, Sodhi N, Anis HK, Ehiorobo JO, Mont MA, Roche MW. Patients who have cannabis use disorder have higher rates of venous thromboemboli, readmission rates, and costs following primary total knee arthroplasty. J Arthroplasty. 2020;35:997–1002.